Search results for "Respiratory Medicine"

showing 10 items of 1534 documents

Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations.

2015

BACKGROUND: Identifying patients at risk of future severe asthma exacerbations, those whose asthma might be less treatment responsive, or both might guide treatment selection. OBJECTIVE: We sought to investigate predictors for failure to achieve Global Initiative for Asthma (GINA)-defined good current asthma control and severe exacerbations on treatment and to develop a simple risk score for exacerbations (RSE) for clinical use. METHODS: A large data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting ?2-agonist therapy was analyzed. Baseline patient characteristics were investigated to determine dominant pre…

BudesonidePediatricsmedicine.medical_specialtyFramingham Risk ScoreMultivariate analysisbusiness.industryRespiratory Medicine and AllergyImmunologymacromolecular substancesmedicine.diseaserespiratory tract diseasesBudesonide/formoterolAsthma Control Questionnaireimmune system diseasesmedicineImmunology and AllergyFormoterolbusinessBody mass indexmedicine.drugAsthma
researchProduct

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct

Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23

2021

Abstract Aims  Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. Methods and results  We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identif…

Cardiac & Cardiovascular SystemsCardiomyopathy Dilated/genetics[SDV]Life Sciences [q-bio]Signal Transducing/geneticsDilated cardiomyopathyGenome-wide association studyAdaptor Proteins Signal Transducing/genetics030204 cardiovascular system & hematologyTAURINE0302 clinical medicineGWASMedicinePOSITION STATEMENT1102 Cardiorespiratory Medicine and HaematologyGenetics0303 health scienceseducation.field_of_studyGenetic Predisposition to Disease/geneticsAdaptor ProteinsDilated cardiomyopathy4C-sequencingPolymorphism Single Nucleotide/geneticsGenetic risk scoreCardiology and Cardiovascular MedicineLife Sciences & BiomedicineSingle Nucleotide/geneticsCardiomyopathy DilatedCardiomyopathyPopulationLocus (genetics)Single-nucleotide polymorphismPolymorphism Single NucleotideChromosomes03 medical and health sciencesSystolic/geneticsHeart Failure Systolic/geneticsSNPAnimalsHumansGenetic Predisposition to DiseaseAllelePolymorphismeducationImputationAdaptor Proteins Signal Transducing030304 developmental biologyHeart FailureScience & Technologybusiness.industryWORKING GROUP1103 Clinical Sciencesmedicine.diseaseGenetic architectureCardiovascular System & Hematology Dilated cardiomyopathyDilated/geneticsCardiovascular System & Cardiology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessApoptosis Regulatory ProteinsHeart Failure SystolicGenome-Wide Association Study
researchProduct

Pulmonary haemodynamics in obstructive sleep apnoea.

1995

In patients with obstructive sleep apnoea syndrome (OSAS), pulmonary haemodynamics can show both transient perturbations during sleep and permanent alterations. During sleep, repeated fluctuations in pulmonary artery pressure and pulmonary wedge pressure, coincident with apnoeas, can be observed. Calculation of transmural pressure values is preferable to intravascular pressures in OSAS, due to the marked swings in intrathoracic pressure associated with obstructive apnoeas. Pulmonary artery pressure may progressively increase during sleep, particularly in close sequences of highly desaturating apnoeas. Apnoea-induced hypoxia appears as the most important determinant of this pulmonary artery …

Cardiac outputPulmonary and Respiratory MedicineCardiac outputmedicine.medical_specialtyHypertension PulmonaryVentricular Dysfunction RightCognitive NeuroscienceSleep REMSettore MED/10 - Malattie Dell'Apparato RespiratorioBehavioral Neurosciencestomatognathic systemPhysiology (medical)Internal medicinemedicine.arteryHumansMedicineRespiratory functionWakefulnessHypoxiaPulmonary wedge pressureLungSleep Apnea Obstructivebusiness.industryHemodynamicsSleep apneaGeneral MedicineStroke volumeHypoxia (medical)medicine.diseasePulmonary artery pressurePulmonary hypertensionnervous system diseasesrespiratory tract diseasesObstructive sleep apneaOphthalmologyStroke volumemedicine.anatomical_structureNeurologyObstructive sleep apnoeaVentricleAnesthesiaPulmonary arteryDentistry (all)CardiologyRight ventricleNeurology (clinical)medicine.symptombusinessJournal of sleep research
researchProduct

May the force be with you: Transfer of healthy mitochondria from stem cells to stroke cells

2018

Stroke is a major cause of death and disability in the United States and around the world with limited therapeutic option. Here, we discuss the critical role of mitochondria in stem cell-mediated rescue of stroke brain by highlighting the concept that deleting the mitochondria from stem cells abolishes the cells’ regenerative potency. The application of innovative approaches entailing generation of mitochondria-voided stem cells as well as pharmacological inhibition of mitochondrial function may elucidate the mechanism underlying transfer of healthy mitochondria to ischemic cells, thereby providing key insights in the pathology and treatment of stroke and other brain disorders plagued with…

Cardiorespiratory Medicine and HaematologyMitochondrionRegenerative medicineRats Sprague-Dawley0302 clinical medicineStem Cell Research - Nonembryonic - Humanenergy metabolismStrokeStem CellsBrainCerebral ischemiaMitochondriaStrokeNeurologycellular bioenergeticStem Cell Research - Nonembryonic - Non-HumanStem cellmedicine.symptomCardiology and Cardiovascular Medicine1.1 Normal biological development and functioningClinical SciencesEnergy metabolismregenerative medicineInflammation03 medical and health sciencesUnderpinning researchmedicineAnimalsHumansNeurology & NeurosurgeryAnimalbusiness.industryMechanism (biology)NeurosciencesStem Cell Researchmedicine.diseaseRatsBrain DisordersTransplantationDisease Models AnimalinflammationDisease ModelsCommentarycellular bioenergeticsSprague-DawleyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgerytransplantationJournal of Cerebral Blood Flow & Metabolism
researchProduct

Effects of sleep apnea and kidney dysfunction on objective sleep quality in nondialyzed patients with chronic kidney disease: an ESADA study

2020

Study Objectives: Patients with chronic kidney disease (CKD) often report poor sleep quality, but they commonly exhibit OSA. The aim of this study was to evaluate the influence of OSA severity and of estimated glomerular filtration rate impairment on objective sleep quality in nondialyzed patients with CKD, defined as an estimated glomerular filtration rate <60 mL/min/1.73m2. Methods: Polysomnographic sleep characteristics were compared between patients with (n = 430) and without CKD (n = 6,639) in the European Sleep Apnea Database cohort. Comparisons were repeated in 375 patients with CKD and 375 control patients without CKD matched for sleep center, age, sex, and AHI, and in 310 matche…

Chronic kidney disease ; Estimated glomerular filtration rate ; Sleep apnea ; Sleep qualitysleep quality.Pulmonary and Respiratory Medicinemedicine.medical_specialtyRenal functionSettore MED/10 - Malattie Dell'Apparato RespiratorioKidneyurologic and male genital diseases03 medical and health sciencesSleep Apnea Syndromes0302 clinical medicinestomatognathic systemChronic kidney diseaseInternal medicineHumansMedicineEstimated glomerular filtration rateRenal Insufficiency ChronicSleep Apnea ObstructiveSleep qualitybusiness.industrySleep apneaKidney dysfunctionSleep apneaSleep qualitymedicine.diseaseScientific Investigationsfemale genital diseases and pregnancy complicationsnervous system diseasesrespiratory tract diseasesPoor sleep030228 respiratory systemNeurologyHuman medicineNeurology (clinical)Sleepbusiness030217 neurology & neurosurgeryKidney diseaseJournal of Clinical Sleep Medicine
researchProduct

Mucosal immunology and probiotics.

2013

The cross-talk between the mucosa-associated immune system and microbiota is critical in mucosal tissue homeostasis as well as in protection against infectious and inflammatory diseases occurring at mucosal sites. This recent evidence has paved the way to therapeutic approaches aimed at modulating the mucosa-associated immune system using probiotics. Different strains of probiotics possess the ability to finely regulate dendritic cell (DC) activation, polarizing the subsequent T cell activity toward Th1 (e.g. Lactobacillus (Lb) acidophilus), Th2 (Lb.reuteri and Bifidobacterium bifidum) or, as more recently demonstrated, Th17 responses induced by specific strains such as Lb.rhamnosus GG and …

Commensal bacteriaSettore MED/07 - Microbiologia E Microbiologia ClinicaAllergyPRRT- cell polarizationved/biology.organism_classification_rank.speciesAutoimmunityProbioticInflammatory bowel diseaseMALTTh1Th2Immunology and AllergyIECBifidobacteriumbiologyMicrobiotaImmune-mediated diseasefood and beveragesPAMPCrohn's diseasemedicine.anatomical_structureMucosal immunologyImmunotherapyTh17HumanPulmonary and Respiratory MedicineSettore MED/17 - Malattie InfettiveT cellImmunologyImmunopathologyDendritic CellMicrobiologyImmune systemBifidobacteriaImmunityTLRmedicineGALTAnimalsHumansImmunity MucosalLABLactobacilluInnate immune systemBifidobacterium bifidumUlcerative colitiMucous Membraneved/biologyAnimalProbioticsDendritic cellDendritic CellsInterleukinbiology.organism_classificationImmunity InnateLactobacillusMucosal immunologyLactobacilliImmune SystemImmunologyBifidobacteriumCurrent allergy and asthma reports
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct